Print Preview Area

Deferasirox Therapy in Children With Fanconi Aplastic Anemia
Journal of Pediatric Hematology/Oncology, 05/14/2012

Tunc B et al. – Deferasirox is an oral, easily applicable, and effective iron chelator; baseline hepatotoxicity and nephrotoxicity may increase the development of toxic side effects in children with Fanconi aplastic anemia (FAA). Patients with FAA receiving deferasirox treatment should be followed up closely for these side effects.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Nursing Jobs
@MDLinx Career Center
View the full listing of nursing jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Deferasirox Therapy in Children With Fanconi Aplastic Anemia Journal of Pediatric Hematology/Oncology, 05/14/2012

Deferasirox Therapy in Children With Fanconi Aplastic Anemia
Journal of Pediatric Hematology/Oncology, 05/14/2012